Delivery of compounds for the treatment of headache through an inhalation route
First Claim
Patent Images
1. A condensation aerosol for delivery of rizatriptan formed by heating a composition containing rizatriptan coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of rizatriptan and less than 5 percent by weight of rizatriptan degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of migraine headache drugs through an inhalation route. Specifically, it relates to aerosols containing migraine headache drugs that are used in inhalation therapy.
-
Citations
54 Claims
- 1. A condensation aerosol for delivery of rizatriptan formed by heating a composition containing rizatriptan coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of rizatriptan and less than 5 percent by weight of rizatriptan degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 4. A condensation aerosol for delivery of zolmitriptan formed by heating a composition containing zolmitriptan coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of zolmitriptan and less than 5 percent by weight of zolmitriptan degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 7. A condensation aerosol for delivery of sumatriptan formed by heating a composition containing sumatriptan coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of sumatriptan and less than 5 percent by weight of sumatriptan degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 10. A condensation aerosol for delivery of frovatriptan formed by heating a composition containing frovatriptan coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of rovatriptan and less than 5 percent by weight of frovatriptan degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 13. A condensation aerosol for delivery of naratriptan formed by heating a composition containing naratriptan coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of naratriptan and less than 5 percent by weight of naratriptan degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
-
16. A method of forming a rizatriptan containing aerosol comprising:
-
(a) heating a composition containing rizatriptan coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of rizatriptan degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (17, 18, 42)
-
-
19. A method of forming a zolmitriptan containing aerosol comprising:
-
(a) heating a composition containing zolmitriptan coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of zolmitriptan degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (20, 21, 43)
-
-
22. A method of forming a sumatriptan containing aerosol comprising:
-
(a) heating a composition containing sumatriptan coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of sumatriptan degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (23, 24, 44)
-
-
25. A method of forming a naratriptan containing aerosol comprising:
-
(a) heating a composition containing naratriptan coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of naratriptan degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (26, 27, 45)
-
-
28. A method of forming a frovatriptan containing aerosol comprising:
-
(a) heating a composition containing frovatriptan coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of frovatriptan degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (29, 30, 46)
-
-
31. A method of forming a drug containing aerosol comprising:
-
(a) heating a composition containing the drug and a pharmaceutically acceptable excipient coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of rizatriptan, zolmitriptan, sumatriptan, frovatriptan, and naratriptan, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (32, 33, 47)
-
-
34. A method of forming a drug containing aerosol comprising:
-
(a) heating a composition containing a salt form of the drug coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of rizatriptan, zolmitriptan, sumatriptan, frovatriptan, and naratriptan, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (35, 36, 48)
-
-
49. A method of forming a drug containing aerosol comprising:
-
(a) heating a composition containing the drug coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of rizatriptan, zolmitriptan, sumatriptan, frovatriptan, and naratriptan, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (50, 51, 52, 53, 54)
-
Specification